Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12076093 | 0.89 | CHRM2 (0.32) | NAMPTHDAC1HDAC2CHRM2CHRM3 | |
| SCHEMBL31548277 | 0.86 | CNR2 (0.37) | NAMPTCNR2MCHR1VNN1CHRM2 | |
| SCHEMBL25075681 | 0.83 | NAMPT (0.41) | NAMPTHDAC1HDAC2CNR2KCNH2 | |
| SCHEMBL29626816 | 0.82 | NAMPT (0.40) | NAMPTHDAC1HDAC2CNR2VNN1 | |
| SCHEMBL368420 | 0.82 | VNN1 (0.40) | NAMPTCNR2KCNH2VNN1OPRK1 | |
| SCHEMBL30900658 | 0.81 | VNN1 (0.38) | NAMPTHDAC1HDAC2CNR2KCNH2 | |
| SCHEMBL31027914 | 0.80 | CHRM2 (0.34) | NAMPTVNN1MEN1LMNAKMT2A | |
| SCHEMBL30545528 | 0.80 | CHRM2 (0.39) | NAMPTVNN1CHRM2CHRM3 | |
| SCHEMBL29619703 | 0.79 | NAMPT (0.44) | NAMPTHDAC1HDAC2CNR2VNN1 | |
| SCHEMBL25629294 | 0.77 | NAMPT (0.38) | NAMPTHDAC1HDAC2CNR2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104154-A1 | 5-[2,7-DIAZASPIRO[3.5]NONAN-7-YL]-5-[4-PHENOXYPHENYL]HEXAHYDROPYRIMIDINE-2,4,6-TRIONE DERIVATIVES AS MMP9 INHIBITORS FOR THE TREATMENT OF DRY EYE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025096858-A1 | COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024073475-A9 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250059200-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| WO-2024175925-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| EP-4413012-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | Studiengesellschaft Kohle gGmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024073475-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023110394-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059200-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | GGH, GEMIN4, GMNN | NAMPT 4632/4885HDAC1 4427/4885HDAC2 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.